Provention Bio Stock News

Provention Bio Inc (NASDAQ: PRVB) announced results from the final analysis of its first-in-human PROVENT study of PRV-101, a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate. Proven

During the last session, Provention Bio Inc. (NASDAQ:PRVB)’s traded shares were 0.32 million, with the beta value of the company hitting 2.59. At the end of the trading day, the stock’s price was $6.50, reflecting an intraday loss of -1.22% or -$0.08. The 52-week high for the PRVB share is $14.14, that puts it down … Provention Bio Inc. (NASDAQ: PRVB): Is It Possible To Be Up 15.66% YTD And Still Lose Money Read More »

The company provided a disappointing Q4 update.

Provention Bio, Inc's. (PRVB) CEO Ashleigh Palmer on Q4 2021 Results - Earnings Call Transcript

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.82% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Provention Bio (NASDAQ:PRVB) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$0.46 (+20.7% Y/Y) and the

The clinical-stage biopharmaceutical company, Provention Bio (PRVB), is trading ~5% higher in the pre-market after the company announced the resubmission of its marketing application

During the last session, Provention Bio Inc. (NASDAQ:PRVB)s traded shares were 0.5 million, with the beta value of the company hitting 2.64. At the end of the trading day, the stocks price was $6.48, reflecting an intraday loss of -3.14% or -$0.21. The 52-week high for the PRVB share is $15.98, that puts it down Provention Bio Inc. (NASDAQ: PRVB) Is Up 51.05% In A Month. Could There Be Any Hope That It Will Rise Soon? Read More »

RED BANK, N.J., Feb. 17, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday,…

RED BANK, N.J., Feb. 10, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the SVB Leerink 11th Annual…

RED BANK, N.J., Feb. 10, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that m

Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 70 + active players working to develop 70 + pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Systemic Lupus Erythematosus treatment scenario include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.